Shun Lü

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · The Lancet Oncology · 2011 · 4.1K citations

Medicine, Oncology, Pharmacology +10

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi‐Long Wu, Caicun Zhou, Chengping Hu et al. · The Lancet Oncology · 2014 · 2K citations

Medicine, Oncology, Pharmacology +11

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu, Masahiro Tsuboi, Jie He et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +15

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler et al. · The Lancet Oncology · 2015 · 1.6K citations

Medicine, Oncology, Pharmacology +13